BOSTON - April 7, 2016 - PRLog -- CSA Medical today announced new clinical data related to its truFreeze® spray cryotherapy system to be presented in a series of oral and poster presentations at Digestive Disease Week® 2016 in San Diego, California.
"CSA Medical initiated a prospective, multi-center patient registry in 2013 to collect efficacy and outcome data related to the use of truFreeze spray cryotherapy for ablation of unwanted tissue in the gastrointestinal area," says Nick Shaheen, M.D., M.P.H. Professor of Medicine and Epidemiology and Director of the Center for Esophageal Diseases & Swallowing at the University of North Carolina. "As Principal Investigator of this study, I am pleased to present interim results which demonstrate the efficacy of truFreeze in a variety of clinical settings."
"Our oral presentation at DDW 2016 will demonstrate the 5 year efficacy and durability of liquid nitrogen spray cryotherapy for the ablation of Barrett's esophagus-associated high grade dysplasia. Sharing our long-term outcomes with other specialists will further demonstrate liquid nitrogen as an effective ablative technology in this area," noted Bruce D. Greenwald, M.D., Professor of Medicine, University of Maryland School of Medicine.
The schedule for the presentations related to truFreeze® spray cryotherapy is presented below:
Saturday, May 21
8:45AM, Room 5
Oral Presentation (2432581): Long-Term Durability of Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus-Associated High Grade Dysplasia: 5-Year Follow Up
Investigators: Fariha H. Ramay, Qingping Cui, Bruce D. Greenwald
9:30AM-4PM, Hall C
Poster (2445560): Liquid Nitrogen Spray Cryotherapy Clinical Outcomes for Barrett's Esophagus Management: Results of a U.S. Multicenter Registry
Investigators: W. A. Wolf, Cary C. Cotton, Matthew McKinley, Vivek Kaul, Shivangi Kothari, Brenda J. Hoffman, Nicholas Shaheen
Monday, May 23
11:15AM, Room 1
Oral Presentation (2445236): Liquid Nitrogen Spray Cryotherapy is a Versatile Management Modality for Pre-Malignant and Malignant Lesions of the Esophagus: Results from a Multicenter U.S. Registry
Investigators: Swathi Eluri, Cary C. Cotton, Brenda J. Hoffman, Vivek Kaul, Matthew McKinley, Nicholas Shaheen
Tuesday, May 24
All Posters 9:30AM-4PM, Hall C
Poster (2441640): Safety and Efficacy of Liquid Nitrogen Cryospray Ablation of Residual Barrett's Esophagus After Endoscopic Resection of Intramucosal Adenocarcinoma: A Multicenter Study
Investigators: Arvind Trindade, Douglas K. Pleskow, Neil Sengupta, Sumant Inamdar, Joshua Berkowitz, Vivek Kaul
Poster (2445928): Liquid Nitrogen Spray Cryotherapy (SCT) Based Multimodal Endoscopic Management of Dysplastic Barrett's and Foregut Neoplasia: Retrospective Review and Long Term Followup at a Single Tertiary Care Referral Center.
Investigators: Shivangi Kothari, Krystle Bittner, Asad Ullah, Vivek Kaul
Poster (2436714): Cryoablation is Associated with Prolonged Stent-Free Survival in Palliative Management of Malignant Dysphagia
Investigators: Daniel K. Chan, Cadman L. Leggett, Liam Zakko, Lori S. Lutzke, Magdalen A. Clemens, Kenneth K. Wang
Poster (2443261): Salvage Cryoablation is Effective for Treating Persistent Dysplasia After Radiofrequency Ablation of Barrett's Esophagus
Investigators: Daniel K. Chan, Cadman L. Leggett, Liam Zakko, Lori S. Lutzke, Magdalen A. Clemens, Kenneth K. Wang
Poster (2432859): Efficacy of Endoscopic Ablation Therapy in Barrett's Esophagus After Esophagectomy
Investigators: Uni Wong, Fariha H. Ramay, Wei-Chung Chen, Lois L. Hemminger, Herbert C. Wolfsen, Vivek Kaul, Thomas J. Watson, Bruce D. Greenwald
Poster (2435957): Liquid Nitrogen Spray Cryotherapy Use for Dysphagia Palliation in Patients With Unresectable Esophageal Cancer: A Retrospective Multicenter Outcomes Study
Investigators: Toufic Kachaamy, Raman Battish, Jeffrey Weber, Scott Hendrickson, Ravi K. Prakash, Rajeev Nayar, Trisha DaSilva DaSilva, Digant Gupta, Pankaj Vashi
For more information related to the truFreeze patient registry, please visit: https://clinicaltrials.gov/ct2/show/NCT01802203?term=CSA+Medical&rank=8
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze® system which is currently used to ablate unwanted benign and malignant tissue.
To learn more about our technology, please visit www.csamedical.com.
Contact
Stephanie Perri
***@csamedical.com
Photos: (Click photo to enlarge)
Read Full Story - CSA Medical Announces Presentations of truFreeze® Clinical Studies at DDW | More news from this source
Press release distribution by PRLog
